Genesis Capital
VC Fund
Central, Hong Kong
Genesis Capital is a VC fund in Central focused on Biotechnology and Artificial Intelligence. Genesis Capital, founded in 2015 by Richard Peng, former corporate Vice President and Head of Investment of Tencent, and Kurt Xu, former Vice General Manager of Investment of Tencent, is a growth capital fund exclusively focused on growth stage Internet companies. We currently manage a USD fund and a RMB fund. We leverage our unparalleled industryexperience to provide critical support to our portfolio companies at critical moments. Together we change the world with great entrepreneurs.
- Total investments:
- 42
- Last investment:
- Lead investor:
- 55%
- Fund size:
- $850M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Genesis Capital invests in
Stages Genesis Capital invests in
Countries Genesis Capital invests in
Investment Focus
Industry
- Biotechnology 8 (19%)
- Artificial Intelligence 8 (19%)
- Health Care 4 (10%)
- Pharmaceutical 4 (10%)
- Medical 3 (7%)
Stage
- Series A 11 (26%)
- Series B 10 (24%)
- Series C 7 (17%)
- Seed 6 (14%)
- Series D 2 (5%)
Country
- China 30 (71%)
- United States 2 (5%)
- Canada 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Huanyu Xinsheng
|
Huanyu Xinsheng is a cutting-edge artificial intelligence startup that focuses on neurocognitive world models. | Seed / Sep 07, 2026 | |
|
Violoop
|
Violoop is a Chinese AI hardware startup Specializes in AI-PC automation hardware as a "physical-level AI Operator", bridging legacy software and AI agents for 24/7 workflows without APIs. | $14.9M / Seed / Sep 01, 2026 | |
|
Yongquan Innovation
|
Yongquan Innovation is a technological firm that specializes in sophisticated desktop CNC machinery. | Seed / Aug 24, 2026 | |
| Looki is building the next generation of human-centric ai platforms - emotionally aware, and deeply embedded in the physical world. | Series A / Jul 14, 2026 | ||
VAST
|
VAST is an artificial intelligence business that develops and manufactures general-purpose 3D big models. Its goal is to develop a popular 3D content production tool, a 3D user-generated content platform, and utilize 3D space to enhance user experience. | $147.3M / Series A / Jul 02, 2026 | |
|
VAST
|
VAST is an artificial intelligence business that develops and manufactures general-purpose 3D big models. Its goal is to develop a popular 3D content production tool, a 3D user-generated content platform, and utilize 3D space to enhance user experience. | $200M / Series A / Jun 01, 2026 | |
| AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $63M / Series B / Sep 21, 2025 | ||
| AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $50.3M / Series B / May 28, 2025 | ||
| AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $37M / Series A / Jul 14, 2024 | ||
| Xunjie Guangyuan operates engages in the research and development of near-infrared spectroscopy analysis instruments. | $14.1M / Series A / May 30, 2024 | ||
| See all 42 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Genesis Capital invest in?
Genesis Capital invests primarily in Biotechnology, Artificial Intelligence and Health Care startups, most often at Series A and Series B stage. Most of the 42 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Genesis Capital last invest?
The most recent investment recorded for Genesis Capital closed in Sep 2026. Shizune tracks 42 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
